A strain-independent postnatal neurodegeneration in mice lacking the EGF receptor.

Por Sibilia, M, Steinbach, J P, Stingl, L, Aguzzi, A, Wagner, E F
Publicado em 1998

P10.04 Anti-angiogenetic Therapy with Bevacizumab for Gliomas with a Gliomatosis Cerebri Growth Pattern

Por Burger, M. C., Mildenberger, I. C., Wagner, M., Mittelbronn, M., Steinbach, J. P.
Publicado no Neuro Oncol (2017)

P01.10 METABOLIC CONDITIONS DETERMINE SENSITIVITY OF GLIOMA CELLS AGAINST EPIDERMAL-GROWTH FACTOR RECEPTOR (EGFR)-INHIBITION

Por Hartel, I.A., Wolking, S., Wanka, C., Ronellenfitsch, M.W., Steinbach, J.P., Rieger, J.
Publicado em 2014

P01.11 The transcriptional coactivator PGC-1a promotes defence against reactive oxygen species (ROS) and proliferation in human glioma cells

Por Hartel, I., Sauer, B., Burger, M., Ronellenfitsch, M. W., Steinbach, J. P., Rieger, J.
Publicado no Neuro Oncol (2016)

P06.05 Myoinositol as a predictive baseline biomarker for overall survival of patients with recurrent glioblastoma treated with Bevacizumab: A 1H-magnetic resonance spectroscopy st...

Por Steidl, E., Pilatus, U., Steinbach, J. P., Zanella, F., Ronellenfitsch, M. W., Hattingen, E., Bähr, O.
Publicado no Neuro Oncol (2016)

OS1.4 Current treatment regimens induce the mTORC1 inhibitor REDD1 in human glioblastoma cells: implications for treatment efficacy

Por Foltyn, M., Thiepold, A., Harter, P. N., Baumgarten, P., Mittelbronn, M., Urban, H., Steinbach, J. P., Ronellenfitsch, M. W.
Publicado no Neuro Oncol (2016)

P04.24 MTOR signaling in glioma-associated microglia and macrophages

Por Zeiner, P S, Lorenz, N I, Burger, M, Luger, A L, Harter, P N, Steinbach, J P, Ronellenfitsch, M W
Publicado no Neuro Oncol (2018)

P04.21 Combination therapy of CAR-NK cells and anti-PD-1 antibody displays potent efficacy against late-stage Glioblastoma and induces protective antitumor immunity

Por Strassheimer, F, Zhang, C, Mildenberger, I C, Harter, P N, Tonn, T, Steinbach, J P, Wels, W S, Burger, M C
Publicado no Neuro Oncol (2018)

P04.47 Nrf2 mediates hypoxic tolerance in human glioblastoma cells

Por Lorenz, N I, Luger, A, Zeiner, P S, Engel, A L, Harter, P N, Steinbach, J P, Ronellenfitsch, M W
Publicado no Neuro Oncol (2018)

O6.05 ERBB2/HER2-SPECIFIC NATURAL KILLER CELLS FOR ADOPTIVE IMMUNOTHERAPY OF GLIOBLASTOMA

Por Burger, M.C., Zhang, C., Jennewein, L., Schönfeld, K., Genßler, S., Grez, M., Tonn, T., Mittelbronn, M., Steinbach, J.P., Wels, W.S.
Publicado em 2014

P16.11 Complete resection is not associated with improved survival in MGMT non-methylated glioblastoma. Results from the GLARIUS trial

Por Kebir, S., Stummer, W., Steinbach, J. P., Weyerbrock, A., Hau, P., Goldbrunner, R., Proescholdt, M., Vatter, H., Herrlinger, U., Glas, M.
Publicado no Neuro Oncol (2017)

P01.03 mTORC1 activation sensitizes human malignant glioma cells to hypoxia-induced cell death by increasing O2-consumption

Por Thiepold, A. L., Foltyn, M., Urban, H., Heller, S., Dröse, S., Harter, P. N., Mittelbronn, M., Steinbach, J. P., Ronellenfitsch, M. W.
Publicado no Neuro Oncol (2016)

P01.101 Treatment and survival of patients with lower grade glioma according to the 2007 and the 2016 WHO classification: A retrospective analysis of 423 patients.

Por Steidl, E, Zeiner, P, Wagner, M, Fokas, E, Forster, M, Ronellenfitsch, M, Steinbach, J P, Harter, P N, Bähr, O
Publicado no Neuro Oncol (2018)

O10.04 THE RANDOMIZED, MULTICENTER GLARIUS TRIAL INVESTIGATING BEVACIZUMAB/IRINOTECAN VS STANDARD TEMOZOLOMIDE IN NEWLY DIAGNOSED, MGMT-NON-METHYLATED GLIOBLASTOMA PATIENTS: FINAL...

Por Herrlinger, U., Schäfer, N., Steinbach, J.P., Weyerbrock, A., Hau, P., Goldbrunner, R., Leutgeb, B., Urbach, H., Stummer, W., Glas, M.
Publicado em 2014

P04.05 The CAR2BRAIN study: a monocentric phase I trial with ErbB2-specific NK-92/5.28.z cells in recurrent glioblastoma

Por Burger, M. C., Mildenberger, I., Zhang, C., Ihrig, K., Wagner, M., Mittelbronn, M., Senft, C., Tonn, T., Wels, W. S., Steinbach, J. P.
Publicado no Neuro Oncol (2016)

P01.31 Mammalian target of rapamycin complex 1 activation sensitizes human glioma cells to hypoxia-induced cell death

Por Thiepold, A., Foltyn, M., Urban, H., Voss, M., Hofmann, U., Dröse, S., Harter, P. N., Mittelbronn, M., Steinbach, J. P., Ronellenfitsch, M. W.
Publicado no Neuro Oncol (2017)

P04.50 Doxycycline impairs mitochondrial function and protects human glioma cells from hypoxia-induced cell death: implications of using Tet-inducible systems

Por Sauer, B, Luger, A, Lorenz, N I, Engel, A L, Braun, Y, Voss, M, Harter, P N, Steinbach, J P, Ronellenfitsch, M W
Publicado no Neuro Oncol (2018)

P07.01 The CAR2BRAIN study: a monocentric phase I trial with ErbB2-specific NK-92/5.28.z cells in recurrent glioblastoma

Por Burger, M. C., Mildenberger, I. C., Cieplik, H. C., Zhang, C., Jennewein, L., Ihrig, K., Wagner, M., Mittelbronn, M., Senft, C., Tonn, T., Wels, W. S., Steinbach, J. P.
Publicado no Neuro Oncol (2017)

P03.21 Casp9 germline mutation in a family with multiple brain tumors

Por Ronellenfitsch, M. W., Oh, J., Satomi, K., Sumi, K., Harter, P. N., Steinbach, J. P., Felsberg, J., Capper, D., Voegele, C., Schittenhelm, J., Mittelbronn, M., Ohgaki, H.
Publicado no Neuro Oncol (2017)

OS2.1 Objective responses to chemotherapy in recurrent glioma do not predict better survival: A prospective analysis from the German Glioma Network

Por Bähr, O, Hentschel, B, Hattingen, E, Reusche, M, Tatagiba, M, Tonn, J, Schnell, O, Schackert, G, Westphal, M, Herrlinger, U, Pietsch, T, Reifenberger, G, Weller, M, Löffler, M, Steinbach, J P
Publicado no Neuro Oncol (2018)